Regulatory Updates
Regulations Amending the Pest Control Products Regulations
Distribution date: 11 March 2014
The proposed regulations notified in G/SPS/N/CAN/627 (dated 17 July 2012) were adopted 26 February 2014 as the Regulations Amending the Pest Control Products Regulations. These Regulations come into force six months after the day on which they are published in the Canada Gazette, Part II.
Products Covered:
Regulation Type: Addendum to Regular Notification
<p><span style="text-decoration:underline;"><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>Notice of Intent to Amend the Prescription Drug List (PDL): Diclofenac</span></span></span></span></p><p><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>The proposed amendment notified in G/TBT/N/CAN/402 (dated 13 November 2013) was adopted 21 February 2014.</span></span></span></p><p align="left" style="background:white;text-align:left;"><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for diclofenac on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged. Health Canada has conducted a scientific review of diclofenac against a set of established and publicly available criteria outlined in section C.01.040.3 of the <em>Food and Drug Regulations</em>. </span></span></span><span style="color:black;"><span lang="EN" style="color:black;">The wording remains unchanged from what was proposed in the Notice of Consultation.</span></span><em></em></p><p align="left" style="background:white;text-align:left;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span lang="EN" style="color:black;font-size:9pt;">This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</span></span></p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-eng.php</a> (English)</p><p><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-fra.php</a> (French)</p><p style="text-align:left;">or requested from:</p><p style="text-align:left;">Canadian Enquiry Point<br />Standards Council of Canada<br />200-270 Albert Street<br />Ottawa, Ontario<br />K1P 6N7<br />Tel.: (613) 238-3222<br />Fax: (613) 569-7808<br />E-mail: <a href="mailto:enquirypoint@scc.ca">enquirypoint@scc.ca</a></p>
Distribution date: 06 March 2014
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p><span style="text-decoration:underline;"><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>Notice of Intent to Amend the Prescription Drug List (PDL): Diclofenac</span></span></span></span></p><p><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>The proposed amendment notified in G/TBT/N/CAN/402 (dated 13 November 2013) was adopted 21 February 2014.</span></span></span></p><p align="left" style="background:white;text-align:left;"><span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="font-size:9pt;"><span>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for diclofenac on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged. Health Canada has conducted a scientific review of diclofenac against a set of established and publicly available criteria outlined in section C.01.040.3 of the <em>Food and Drug Regulations</em>. </span></span></span><span style="color:black;"><span lang="EN" style="color:black;">The wording remains unchanged from what was proposed in the Notice of Consultation.</span></span><em></em></p><p align="left" style="background:white;text-align:left;"><span style="color:black;font-size:x-small;font-face:Verdana;"><span lang="EN" style="color:black;font-size:9pt;">This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</span></span></p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-eng.php</a> (English)</p><p><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_diclofenac-fra.php</a> (French)</p><p style="text-align:left;">or requested from:</p><p style="text-align:left;">Canadian Enquiry Point<br />Standards Council of Canada<br />200-270 Albert Street<br />Ottawa, Ontario<br />K1P 6N7<br />Tel.: (613) 238-3222<br />Fax: (613) 569-7808<br />E-mail: <a href="mailto:enquirypoint@scc.ca">enquirypoint@scc.ca</a></p>
Distribution date: 06 March 2014
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p><span style="text-decoration:underline;">Notice of Intent to Amend the Prescription Drug List (PDL): Minoxidil</span></p><p>The proposed amendment notified in G/TBT/N/CAN/400 (dated 13 November 2013) was adopted 21 February 2014.</p><p>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for minoxidil on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged. Health Canada has conducted a scientific review of minoxidil against a set of established and publicly available criteria outlined in section C.01.040.3 of the <em>Food and Drug Regulations</em>. The wording remains unchanged from what was proposed in the Notice of Consultation.</p><p>This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-eng.php</a> (English)</p><p><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-fra.php</a> <br />(French)</p><p style="text-align:left;">or requested from:</p><p style="text-align:left;">Canadian Enquiry Point<br />Standards Council of Canada<br />200-270 Albert Street<br />Ottawa, Ontario<br />K1P 6N7<br />Tel.: (613) 238-3222<br />Fax: (613) 569-7808<br />E-mail: <a href="mailto:enquirypoint@scc.ca">enquirypoint@scc.ca</a></p>
Distribution date: 06 March 2014
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
<p><span style="text-decoration:underline;">Notice of Intent to Amend the Prescription Drug List (PDL): Minoxidil</span></p><p>The proposed amendment notified in G/TBT/N/CAN/400 (dated 13 November 2013) was adopted 21 February 2014.</p><p>The purpose of this Notice of Intent to Amend is to notify that, as a result of consultation, Health Canada will revise the listing for minoxidil on the Prescription Drug List (PDL). Only the Human part of the PDL is to be revised; the listing for Veterinary use will remain unchanged. Health Canada has conducted a scientific review of minoxidil against a set of established and publicly available criteria outlined in section C.01.040.3 of the <em>Food and Drug Regulations</em>. The wording remains unchanged from what was proposed in the Notice of Consultation.</p><p>This revision will be in effect six months from the date of this Notice posted on the Health Canada website.</p><p>The full text of the adopted measure can be downloaded from the Internet addresses indicated below:<br /><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-eng.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-eng.php</a> (English)</p><p><a href="http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-fra.php">http://www.hc-sc.gc.ca/dhp-mps/prodpharma/pdl-ord/pdl_ldo_noi_adi_minoxidil-fra.php</a> <br />(French)</p><p style="text-align:left;">or requested from:</p><p style="text-align:left;">Canadian Enquiry Point<br />Standards Council of Canada<br />200-270 Albert Street<br />Ottawa, Ontario<br />K1P 6N7<br />Tel.: (613) 238-3222<br />Fax: (613) 569-7808<br />E-mail: <a href="mailto:enquirypoint@scc.ca">enquirypoint@scc.ca</a></p>
Distribution date: 06 March 2014
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Addendum to Regular Notification
Notice of Consultation- Prescription Drug List (PDL): Hydrocortisone (3 pages, in English and French) .
Distribution date: 05 March 2014 | Final date for Comment: 04 May 2014
<span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;mso-bidi-font-size:11.0pt;mso-fareast-font-family:Calibri;mso-bidi-font-family:'Times New Roman';mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:AR-SA;">The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for hydrocortisone on the Prescription Drug List (PDL).</span></span>
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Regular notification
Notice of Consultation- Prescription Drug List (PDL): Hydrocortisone (3 pages, in English and French) .
Distribution date: 05 March 2014 | Final date for Comment: 04 May 2014
<span style="font-size:x-small;font-face:Verdana;"><span lang="EN-GB" style="letter-spacing:-0.1pt;font-family:'Verdana','sans-serif';font-size:9pt;mso-bidi-font-size:11.0pt;mso-fareast-font-family:Calibri;mso-bidi-font-family:'Times New Roman';mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;mso-bidi-language:AR-SA;">The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for hydrocortisone on the Prescription Drug List (PDL).</span></span>
Products Covered: Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)
Regulation Type: Regular notification
; ; ;The Republic of Ecuador hereby advises that the first revision (1R) of Ecuadorian Standardization Institute Technical Regulation (RTE INEN) No. 061 "Paint", notified in document G/TBT/N/ECU/77/Add.1 of 8 May 2012, was issued pursuant to Resolution No. 13 373 of 22 October 2013 of the Under-Secretariat for Quality of the Ministry of Industry and Productivity, published in Official Journal No. 123 of 14 November 2013. ; ;Text available from: ; ;Ministerio de Industrias y Productividad (Ministry of Industry and Productivity) ;Subsecretaría de la Calidad (Under-Secretariat for Quality) ;Organismo Nacional encargado de la Notificación (National Notification Authority) ; ;Contact person: Marlon Martínez B. ;Yánez Pinzón No. 26-12 y Av. Colón, Edf. Rigel ;Quito, Ecuador ;Tel.: +593 2 394-8760, Ext. 2358/2255 ;Email: PuntocontactoOTCECU@mipro.gob.ec; mmartinez@mipro.gob.ec ;Text available online at: http://members.wto.org/crnattachments/2014/tbt/ECU/14_1015_00_s.pdf ; ;
Distribution date: 03 March 2014
Products Covered: 3208100000, 3208200000, 3208900000, 3209100000, 3209900000, 3210001000, 3210002000, 3210009000
Regulation Type: Addendum to Regular Notification
; ; ;The Republic of Ecuador hereby advises that the first revision (1R) of Ecuadorian Standardization Institute Technical Regulation (RTE INEN) No. 061 "Paint", notified in document G/TBT/N/ECU/77/Add.1 of 8 May 2012, was issued pursuant to Resolution No. 13 373 of 22 October 2013 of the Under-Secretariat for Quality of the Ministry of Industry and Productivity, published in Official Journal No. 123 of 14 November 2013. ; ;Text available from: ; ;Ministerio de Industrias y Productividad (Ministry of Industry and Productivity) ;Subsecretaría de la Calidad (Under-Secretariat for Quality) ;Organismo Nacional encargado de la Notificación (National Notification Authority) ; ;Contact person: Marlon Martínez B. ;Yánez Pinzón No. 26-12 y Av. Colón, Edf. Rigel ;Quito, Ecuador ;Tel.: +593 2 394-8760, Ext. 2358/2255 ;Email: PuntocontactoOTCECU@mipro.gob.ec; mmartinez@mipro.gob.ec ;Text available online at: http://members.wto.org/crnattachments/2014/tbt/ECU/14_1015_00_s.pdf ; ;
Distribution date: 03 March 2014
Products Covered: 3208100000, 3208200000, 3208900000, 3209100000, 3209900000, 3210001000, 3210002000, 3210009000
Regulation Type: Addendum to Regular Notification
; ; ;By means of this Addendum No. 2, the Republic of Ecuador advises that Amendment No. 2 to Emergency Technical Regulation of the Ecuadorian Standardization Institute (RTE INEN) No. 093 "Cosmetic products", notified in document G/TBT/N/ECU/116 of 22 November 2013, was issued pursuant to Resolution No. 14 042 of 30 January 2014 of the Under-Secretariat for Quality of the Ministry of Industry and Productivity, published in Official Journal No. 187 of Wednesday 19 February 2014. ; ;Text available from: ; ;Ministerio de Industrias y Productividad (Ministry of Industry and Productivity) ;Subsecretaría de la Calidad (Under-Secretariat for Quality) ;Organismo Nacional encargado de la Notificación (National Notification Authority) ; ;Contact person: Marlon Martínez B. ;Yánez Pinzón No. 26-12 y Av. Colón, Edf. Rigel ;Quito, Ecuador ;Tel.: +593 2 394-8760, Ext. 2358/2255 ;Email: puntocontactoOTCECU@mipro.gob.ec; mmartinez@mipro.gob.ec ; ;
Distribution date: 03 March 2014
Products Covered: 3303.00.00.00, 3304.10.00.00, 3304.20.00.00, 3304.30.00.00, 3304.91.00.00, 3305.10.00.00, 3305.20.00.00, 3305.30.00.00, 3305.90.00.00, 3306.10.00.00, 3306.90.00.00, 3307.10.00.00, 3307.20.00.00, 3307.30.00.00 and 3307.90.90.00 ;
Regulation Type: Addendum to Regular Notification
Submit your email ID to receive notifications about upcoming courses and events